Impedance-based analysis systems, such as the RTCA Cardio xCELLigence (ACEA Biosciences) and the CardioExcyte (Nanion Technologies), enable continous, label-free measurement of cardiomyocyte function. The combination of spontaneously-beating Cor.4U® human iPS cell-derived cardiomyocytes with this non-invasive assay allows researchers to detect drug-induced acute (minutes to hours) and long-term (days to weeks) changes in cell viability and cell contractility within a single experiment in a 96-well format. The online and continuous high-resolution cell monitoring allows for accurate identification of cardiotoxicity and proarrhythmic risk of drug candidates.
- Label-free, continous measurement of spontaneously-beating human iPS cell-derived cardiomyocytes.
- Accurate identification of both structural cardiotoxicity and proarrhythmic risk of drug candidates.
- Highly standardized cell model in combination with high-resolution cell monitoring to rule out cardiotoxic compounds earlier in discovery.